NCT00290277View on ClinicalTrials.gov

Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years

PHASE3CompletedINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

August 31, 2006

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

HPV-16/18 L1/AS04

Trial Locations (8)

700-712

GSK Investigational Site, Daegu

Unknown

GSK Investigational Site, Kwangju

110-744

GSK Investigational Site, Seoul

133--792

GSK Investigational Site, Seoul

135-710

GSK Investigational Site, Seoul

135-720

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00290277 - Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years | Biotech Hunter | Biotech Hunter